Elevated INR is an Absolute Contraindication to TNK
An elevated INR >1.7 is an absolute contraindication to tenecteplase (TNK) administration, and treatment should not be initiated or must be discontinued if this threshold is exceeded. 1
FDA-Mandated Contraindications
The FDA drug label for TNKase explicitly lists "known bleeding diathesis" as an absolute contraindication 1. More specifically, the safety and efficacy of TNK in patients with INR >1.7 are unknown, and TNK should not be administered under these conditions 2, 1.
Critical Implementation Points:
- In patients without recent oral anticoagulant use: TNK can be initiated before coagulation results are available, but must be discontinued immediately if INR returns >1.7 2
- In patients on vitamin K antagonists (VKA): If INR ≥1.4, reversal with vitamin K 10 mg IV plus prothrombin complex concentrate (PCC) or fresh frozen plasma is required before considering any thrombolytic therapy 3
- The INR cutoff of 1.7 applies specifically to acute stroke thrombolysis protocols 2
Context and Nuance
Why This Threshold Exists:
The INR was designed and validated specifically for monitoring VKA therapy 4. When used outside this context, its predictive value for bleeding is limited 5, 4. However, the 1.7 threshold remains a regulatory standard because:
- Regulatory precedent: Clinical trials establishing TNK safety excluded patients with INR >1.7 2
- Medicolegal protection: The FDA contraindication provides clear guidance despite imperfect evidence
- Practical risk stratification: While INR poorly predicts bleeding in non-VKA contexts, values >1.7 suggest significant coagulation abnormality requiring investigation 6
Common Pitfalls:
Do not dismiss elevated INR as "just a lab value" in patients on direct oral anticoagulants (DOACs). While DOACs can prolong INR, elevated values still correlate with increased mortality risk and should prompt careful evaluation 7. However, the 1.7 cutoff specifically applies to traditional coagulation assessment, not DOAC monitoring.
Post-thrombolytic INR elevation can occur as a transient phenomenon after tPA/TNK administration (mean INR 2.03, occurring within 5.4 hours post-treatment) 8. This represents consumptive coagulopathy with hypofibrinogenemia and requires monitoring, though it differs from pre-treatment contraindications.
For Patients on Anticoagulation:
- VKA therapy: Absolute contraindication unless INR <1.7 2
- DOACs: Different consideration—contraindicated unless appropriate laboratory tests (aPTT, INR, direct factor Xa assays) are normal OR >48 hours since last dose with normal renal function 2
- Therapeutic heparin within 48 hours: Check aPTT; contraindicated if >40 seconds 2
Practical Algorithm:
- Check INR immediately in all stroke patients being considered for TNK
- If INR <1.7 and no recent anticoagulant use: Proceed with TNK if otherwise eligible
- If INR ≥1.7: Do not administer TNK; consider mechanical thrombectomy instead
- If on VKA with INR ≥1.4: Reverse with vitamin K + PCC before any reperfusion consideration 3
- If results pending but no anticoagulant history: May initiate TNK but discontinue immediately if INR returns >1.7 2
The evidence consistently supports that while INR has limitations as a bleeding predictor in non-VKA contexts 5, 4, the regulatory threshold of 1.7 remains an absolute contraindication for TNK administration based on trial exclusion criteria and FDA labeling 2, 1.